1-3 of 3
Karen Habucky, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib As First-Line Therapy in the United States

Karen Seiter, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Briana Ndife, MPH, Karen Habucky, PhD, George J Joseph, BPharm, MS, PhD, Irina Pivneva, PhD, Patrick Gagnon-Sanschagrin, MS, Derek H Tang, BSPharm, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3391.
https://doi.org/10.1182/blood.V130.Suppl_1.3391.3391
Published: 2017
Journal Articles

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in US Clinical Practice, with a Focus on Tyrosine Kinase Inhibitor Therapy Discontinuation

Ellen K Ritchie, MD, Dominick Latremouille-Viau, Annie Guerin, MS, Irina Pivneva, PhD, Karen Habucky, PhD, Briana Ndife, MPH, George J Joseph, BPharm, MS, PhD, Ehab Atallah, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3396.
https://doi.org/10.1182/blood.V130.Suppl_1.3396.3396
Published: 2017
Journal Articles

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Ellen K Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, MD, Michael R. Savona, MD, Ilva Dautaj, MS, Das Purkayastha, Karen Habucky, PhD, Michael J. Mauro, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2875.
https://doi.org/10.1182/blood.V130.Suppl_1.2875.2875
Published: 2017